

Multipeptide immune response to cancer vaccine IMA9 cyclophosphamide associates with longer patient survival

Nature Medicine

18, 1254-1261

DOI: [10.1038/nm.2883](https://doi.org/10.1038/nm.2883)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Clinical experiences of combining immunotherapy and radiation therapy in non-small cell lung cancer: lessons from melanoma. <i>Translational Lung Cancer Research</i> , 2007, 6, 169-177.	1.3	4
2	How can chemoimmunotherapy best be used for the treatment of colon cancer?. <i>Immunotherapy</i> , 2012, 4, 1787-1790.	1.0	3
3	Entwicklung therapeutischer Peptidimpfstoffe gegen Krebs. <i>Arzneimittelforschung</i> , 2012, 62, S5-S7.	0.5	0
4	Trial watch. <i>Oncolmmunology</i> , 2012, 1, 1557-1576.	2.1	110
5	Survival benefit of RCC vaccine. <i>Nature Reviews Urology</i> , 2012, 9, 545-545.	1.9	1
7	Tailor-Made Renal Cell Carcinoma Vaccines. <i>Cancer Cell</i> , 2012, 22, 287-289.	7.7	3
8	Immune Tolerance to Tumor Antigens Occurs in a Specialized Environment of the Spleen. <i>Cell Reports</i> , 2012, 2, 628-639.	2.9	196
9	Inflammatory prognostic markers in clear cell renal cell carcinoma " preoperative <sc>C</sc>" reactive protein does not improve predictive accuracy. <i>BJU International</i> , 2012, 110, E771-7.	1.3	17
10	Harmonizing the immune response with a cancer vaccine. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 487-487.	12.5	4
11	Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer. <i>Journal of Translational Medicine</i> , 2013, 11, 97.	1.8	60
12	The Dark Side of Cyclophosphamide: Cyclophosphamide-Mediated Ablation of Regulatory T Cells. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1462-1465.	0.3	19
13	A high throughput method for enrichment of natural killer cells and lymphocytes and assessment of in vitro cytotoxicity. <i>Journal of Immunological Methods</i> , 2013, 394, 40-48.	0.6	10
14	Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 911-925.	1.4	16
15	IMA901: a peptide vaccine in renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1329-1336.	1.9	12
16	Functional characterization of Foxp3-specific spontaneous immune responses. <i>Leukemia</i> , 2013, 27, 2332-2340.	3.3	23
17	Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors. , 2013, 1, 11.		56
18	Focus on the target: the tumor microenvironment, Society for Immunotherapy of Cancer Annual Meeting Workshop, October 24th-25th 2012. , 2013, 1, 9.		3
19	Immune monitoring using the predictive power of immune profiles. , 2013, 1, 7.		50

#	ARTICLE	IF	CITATIONS
20	A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1041-1052.	2.0	55
21	Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 897-908.	2.0	31
22	Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 909-918.	2.0	268
23	Dendritic-Cell-Based Therapeutic Cancer Vaccines. <i>Immunity</i> , 2013, 39, 38-48.	6.6	739
24	The repertoire of human tumor-associated epitopes – identification and selection of antigens and their application in clinical trials. <i>Current Opinion in Immunology</i> , 2013, 25, 277-283.	2.4	39
25	Role of vaccine therapy for renal cell carcinoma in the era of targeted therapy. <i>International Journal of Urology</i> , 2013, 20, 744-755.	0.5	11
26	Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. <i>Seminars in Immunology</i> , 2013, 25, 182-190.	2.7	44
27	HLA Class I Expression in Human Cancer. , 2013, , 13-30.		0
28	Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly. <i>Immunologic Research</i> , 2013, 57, 172-184.	1.3	89
29	GM-CSF Promotes the Immunosuppressive Activity of Glioma-Infiltrating Myeloid Cells through Interleukin-4 Receptor- α . <i>Cancer Research</i> , 2013, 73, 6413-6423.	0.4	169
30	Immune-Checkpoint Blockade and Active Immunotherapy for Glioma. <i>Cancers</i> , 2013, 5, 1379-1412.	1.7	33
31	Prothymosin α and a prothymosin α -derived peptide enhance TH1-type immune responses against defined HER-2/neu epitopes. <i>BMC Immunology</i> , 2013, 14, 43.	0.9	22
32	Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1399-1408.	1.1	10
33	Development of a peptide-based vaccine targeting TMPRSS2:ERG fusion-positive prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1831-1840.	2.0	14
34	Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1521-1531.	2.0	38
35	HLA ligandome tumor antigen discovery for personalized vaccine approach. <i>Expert Review of Vaccines</i> , 2013, 12, 1211-1217.	2.0	87
36	Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions. <i>Expert Review of Vaccines</i> , 2013, 12, 1219-1234.	2.0	8
37	Highly Optimized DNA Vaccine Targeting Human Telomerase Reverse Transcriptase Stimulates Potent Antitumor Immunity. <i>Cancer Immunology Research</i> , 2013, 1, 179-189.	1.6	48

#	ARTICLE	IF	CITATIONS
38	Chemoimmunotherapy: reengineering tumor immunity. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 203-216.	2.0	215
39	Challenges in cancer vaccine development for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2013, 59, 897-903.	1.8	87
40	High-throughput screening of tumor metastatic-related differential glycoprotein in hepatocellular carcinoma by iTRAQ combines lectin-related techniques. <i>Medical Oncology</i> , 2013, 30, 420.	1.2	27
41	Next-generation peptide vaccines for advanced cancer. <i>Cancer Science</i> , 2013, 104, 15-21.	1.7	108
42	The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. <i>Immunology</i> , 2013, 138, 105-115.	2.0	643
43	Human cancer regression antigens. <i>Current Opinion in Immunology</i> , 2013, 25, 284-290.	2.4	38
44	Increased CD14+HLA-DR-/low myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1439-1451.	2.0	194
45	Peripheral CD8+ T cell proliferation is prognostic for patients with advanced thoracic malignancies. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 529-539.	2.0	21
46	Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity. <i>Frontiers in Immunology</i> , 2013, 4, 438.	2.2	289
47	Home Sweet Home: The Tumor Microenvironment as a Haven for Regulatory T Cells. <i>Frontiers in Immunology</i> , 2013, 4, 197.	2.2	70
48	Natural and Induced T Regulatory Cells in Cancer. <i>Frontiers in Immunology</i> , 2013, 4, 190.	2.2	202
49	Immunological Monitoring to Rationally Guide AAV Gene Therapy. <i>Frontiers in Immunology</i> , 2013, 4, 273.	2.2	14
50	Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes. <i>Oncolmmunology</i> , 2013, 2, e26014.	2.1	20
51	Modeling Tumor Response after Combined Administration of Different Immune-Stimulatory Agents. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 346, 432-442.	1.3	19
52	Modification of the Tumor Microenvironment as a Novel Target of Renal Cell Carcinoma Therapeutics. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 353-364.	1.0	48
53	A New Age for Vaccine Therapy in Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 365-370.	1.0	18
54	Alkylating chemotherapy may exert a uniquely deleterious effect upon neo-antigen-targeting anticancer vaccination. <i>Oncolmmunology</i> , 2013, 2, e26294.	2.1	18
55	Advances in the study of HLA-restricted epitope vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2566-2577.	1.4	44

#	ARTICLE	IF	CITATIONS
57	FOXP3-specific immunity. <i>Oncolimmunology</i> , 2013, 2, e26247.	2.1	6
58	Cancer vaccines. <i>Oncolimmunology</i> , 2013, 2, e23403.	2.1	62
59	Recent developments in the treatment of renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2013, 5, 338-353.	0.9	64
60	Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICOâ€”The MIMOSA Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 1554-1561.	0.8	126
61	â€œLicense to Killâ€•Reflects Joint Action of CD4 and CD8 T Cells. <i>Clinical Cancer Research</i> , 2013, 19, 4295-4296.	3.2	24
62	Clinical Perspectives on Targeting of Myeloid Derived Suppressor Cells in the Treatment of Cancer. <i>Frontiers in Oncology</i> , 2013, 3, 49.	1.3	133
63	Increased Myeloid-Derived Suppressor Cells in Gastric Cancer Correlate with Cancer Stage and Plasma S100A8/A9 Proinflammatory Proteins. <i>Journal of Immunology</i> , 2013, 190, 794-804.	0.4	216
64	Cancer vaccines: Identification of biomarkers predictive of clinical efficacy. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 800-804.	1.4	3
65	Identification of Promiscuous KIF20A Long Peptides Bearing Both CD4+ and CD8+ T-cell Epitopes: KIF20A-Specific CD4+ T-cell Immunity in Patients with Malignant Tumor. <i>Clinical Cancer Research</i> , 2013, 19, 4508-4520.	3.2	53
66	Clinical and immunologic responses in melanoma patients vaccinated with MAGEâ€”genetically modified lymphocytes. <i>International Journal of Cancer</i> , 2013, 132, 2557-2566.	2.3	20
67	Generation of more effective cancer vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2543-2547.	1.4	11
68	A novel, disruptive vaccination technology. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2263-2276.	1.4	171
69	Immunotherapy of HPV-associated head and neck cancer. <i>Oncolimmunology</i> , 2013, 2, e24534.	2.1	12
70	Profound Impairment of Adaptive Immune Responses by Alkylating Chemotherapy. <i>Journal of Immunology</i> , 2013, 190, 6259-6268.	0.4	64
71	Following up tumor-specific regulatory T cells in cancer patients. <i>Oncolimmunology</i> , 2013, 2, e25444.	2.1	21
72	Trial watch. <i>Oncolimmunology</i> , 2013, 2, e23510.	2.1	153
73	Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901. <i>Oncolimmunology</i> , 2013, 2, e22246.	2.1	31
74	Biodegradable particles as vaccine antigen delivery systems for stimulating cellular immune responses. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2584-2590.	1.4	63

#	ARTICLE	IF	CITATIONS
75	Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2013, 108, 1260-1266.	2.9	36
76	A Randomized Phase II Trial of Multiepitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602). <i>Clinical Cancer Research</i> , 2013, 19, 4228-4238.	3.2	98
78	Circulating and Tumor-Infiltrating Myeloid-Derived Suppressor Cells in Patients with Colorectal Carcinoma. <i>PLoS ONE</i> , 2013, 8, e57114.	1.1	232
79	Identification and Enhancement of HLA-A2.1-Restricted CTL Epitopes in a New Human Cancer Antigen-POTE. <i>PLoS ONE</i> , 2013, 8, e64365.	1.1	15
80	How to detour Treg cells in T cell-based antitumor immune therapy. <i>OncoTargets and Therapy</i> , 2013, 6, 1243.	1.0	2
81	Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Perspectives. , 2013, , .		2
82	Therapeutic cancer vaccines and combination immunotherapies involving vaccination. <i>ImmunoTargets and Therapy</i> , 2014, 3, 135.	2.7	9
83	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	0.8	395
84	Managing Multi-center Flow Cytometry Data for Immune Monitoring. <i>Cancer Informatics</i> , 2014, 13s7, CIN.S16346.	0.9	9
85	The preoperative lymphocyte to monocyte ratio predicts clinical outcomes in patients with stage II/III gastric cancer. <i>Tumor Biology</i> , 2014, 35, 11659-11666.	0.8	58
86	Recent advances in immunotherapy for non-small-cell lung cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 352-357.	1.4	16
87	IMA901: A multi-peptide cancer vaccine for treatment of renal cell cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3179-3189.	1.4	44
89	Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: An exploratory study. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3394-3408.	1.4	14
90	Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer. <i>Expert Review of Vaccines</i> , 2014, 13, 87-116.	2.0	3
91	Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells. <i>Oncolmmunology</i> , 2014, 3, e970914.	2.1	21
92	New concepts of biomarkers and clinical outcomes for therapeutic cancer vaccines in clinical trials. <i>Immunotherapy</i> , 2014, 6, 1025-1036.	1.0	3
93	Monocytic myeloid-derived suppressor cells in advanced melanoma patients. <i>Oncolmmunology</i> , 2014, 3, e27845.	2.1	17
94	Identification of immunogenic LY6K long peptide encompassing both CD4 ⁺ and CD8 ⁺ T-cell epitopes and eliciting CD4 ⁺ T-cell immunity in patients with malignant disease. <i>Oncolmmunology</i> , 2014, 3, e28100.	2.1	17

#	ARTICLE	IF	CITATIONS
95	A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinoma. <i>Immunotherapy</i> , 2014, 6, 261-268.	1.0	5
96	Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity. <i>Cell Death and Disease</i> , 2014, 5, e1568-e1568.	2.7	42
97	Therapeutic targeting of naturally presented myeloperoxidase-derived HLA peptide ligands on myeloid leukemia cells by TCR-transgenic T cells. <i>Leukemia</i> , 2014, 28, 2355-2366.	3.3	21
98	Mass spectrometry in cancer biomarker research: a case for immunodepletion of abundant blood-derived proteins from clinical tissue specimens. <i>Biomarkers in Medicine</i> , 2014, 8, 269-286.	0.6	34
99	Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy. <i>British Journal of Cancer</i> , 2014, 111, 1350-1362.	2.9	21
100	5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies. <i>Blood Cancer Journal</i> , 2014, 4, e197-e197.	2.8	67
101	Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A-specific T Cells. <i>Clinical Cancer Research</i> , 2014, 20, 1601-1609.	3.2	222
102	Modes of action of TLR7 agonists in cancer therapy. <i>Immunotherapy</i> , 2014, 6, 1085-1095.	1.0	66
103	Cancer Stem Cell Immunology: Key to Understanding Tumorigenesis and Tumor Immune Escape?. <i>Frontiers in Immunology</i> , 2014, 5, 360.	2.2	147
104	Induction of HLA-A*33-restricted cytotoxic lymphocytes against renal cell carcinoma targeting galectin 9 and PINCH. <i>Biomedical Reports</i> , 2014, 2, 809-812.	0.9	4
105	Clear Cell Renal Cell Carcinoma as a Model of Pathological Angiogenesis: Which Actors to Target for Treatment?. , 2014, , 112-131.		0
106	The Role of Inflammation in Kidney Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2014, 816, 197-234.	0.8	83
107	Boosting the MHC Class II-Restricted Tumor Antigen Presentation to CD4+ T Helper Cells: A Critical Issue for Triggering Protective Immunity and Re-Orienting the Tumor Microenvironment Toward an Anti-Tumor State. <i>Frontiers in Oncology</i> , 2014, 4, 32.	1.3	40
108	Therapeutic cancer vaccines: a long and winding road to success. <i>Expert Review of Vaccines</i> , 2014, 13, 131-144.	2.0	12
109	Identification of CDCA1-derived long peptides bearing both CD4 ⁺ and CD8 ⁺ T cell epitopes: CDCA1-specific CD4 ⁺ T cell immunity in cancer patients. <i>International Journal of Cancer</i> , 2014, 134, 352-366.	2.3	23
110	Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 1177-1187.	2.0	135
111	Complexity and challenges in defining myeloid-derived suppressor cells. , 2014, , n/a-n/a.		102
112	Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19-IL2 Results in Sustained Clinical and Systemic Immunologic Responses. <i>Cancer Immunology Research</i> , 2014, 2, 668-678.	1.6	81

#	ARTICLE	IF	CITATIONS
113	PD-1 Blockade in Renal Cell Carcinoma: To Equilibrium and Beyond. <i>Cancer Immunology Research</i> , 2014, 2, 1132-1141.	1.6	42
114	Enzymatic generation of peptides flanked by basic amino acids to obtain MS/MS spectra with 2Å– sequence coverage. <i>Rapid Communications in Mass Spectrometry</i> , 2014, 28, 2735-2743.	0.7	8
115	A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSFâ€“Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer. <i>Cancer Immunology Research</i> , 2014, 2, 949-961.	1.6	77
116	APOA1 mRNA Expression in Ovarian Serous Carcinoma Effusions Is a Marker of Longer Survival. <i>American Journal of Clinical Pathology</i> , 2014, 142, 51-57.	0.4	28
117	Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. , 2014, 2, 31.		92
118	Axitinib for the treatment of advanced renal cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 283-297.	0.9	14
119	Implementing combinatorial immunotherapeutic regimens against cancer. <i>Oncolmunology</i> , 2014, 3, e27588.	2.1	13
120	Clinical validation of IFNÎ³/IL-10 and IFNÎ³/IL-2 FluoroSpot assays for the detection of Tr1 T cells and influenza vaccine monitoring in humans. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 104-113.	1.4	17
121	Therapeutic Cancer Vaccines. <i>Advances in Cancer Research</i> , 2014, 121, 67-124.	1.9	68
122	Adjuvant Therapy for Renal Cell Carcinoma: Past, Present, and Future. <i>Oncologist</i> , 2014, 19, 851-859.	1.9	57
123	IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy. <i>Future Oncology</i> , 2014, 10, 937-948.	1.1	10
124	Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1. <i>Frontiers in Immunology</i> , 2014, 5, 206.	2.2	108
125	Poxviral-based vaccine elicits immunologic responses in prostate cancer patients. <i>Oncolmunology</i> , 2014, 3, e28611.	2.1	14
126	Frequent T cell responses against immunogenic targets in lung cancer patients for targeted immunotherapy. <i>Oncology Reports</i> , 2014, 31, 384-390.	1.2	19
127	Immunoguiding, the Final Frontier in the Immunotherapy of Cancer. , 2014, , 37-51.		0
128	A Circulating Subpopulation of Monocytic Myeloid-Derived Suppressor Cells as an Independent Prognostic/Predictive Factor in Untreated Non-Small Lung Cancer Patients. <i>Journal of Immunology Research</i> , 2014, 2014, 1-12.	0.9	106
129	Dendritic Cell-Based Approaches in the Fight Against Diseases. <i>Frontiers in Immunology</i> , 2014, 5, 78.	2.2	15
130	Immunotherapy of hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2014, 1, 433-446.	4.2	5

#	ARTICLE	IF	CITATIONS
131	Combination of cancer immunotherapy with clinically available drugs that can block immunosuppressive cells. <i>Immunological Investigations</i> , 2014, 43, 517-534.	1.0	10
132	Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer. <i>Journal of Geriatric Oncology</i> , 2014, 5, 156-163.	0.5	22
133	Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy. <i>World Journal of Urology</i> , 2014, 32, 31-38.	1.2	28
134	Advances in the quantification of protein microarrays. <i>Current Opinion in Chemical Biology</i> , 2014, 18, 16-20.	2.8	17
136	Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 247-257.	2.0	472
137	Monitoring the immune competence of cancer patients to predict outcome. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 713-719.	2.0	39
138	An impedance-based cytotoxicity assay for real-time and label-free assessment of T-cell-mediated killing of adherent cells. <i>Journal of Immunological Methods</i> , 2014, 405, 192-198.	0.6	59
139	Signaling pathways involved in MDSC regulation. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 55-65.	3.3	152
140	Humoral response to a viral glycan correlates with survival on PROSTVAC-VF. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E1749-58.	3.3	41
142	Obesity and renal cancer. <i>Oncolmmunology</i> , 2014, 3, e27810.	2.1	55
143	Effects of obesity on immune responses to renal tumors. <i>Immunologic Research</i> , 2014, 59, 211-219.	1.3	2
144	Immunological challenges for peptide-based immunotherapy in glioblastoma. <i>Cancer Treatment Reviews</i> , 2014, 40, 248-258.	3.4	47
145	Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 24-37.	12.5	380
146	Induced regulatory T cells in inhibitory microenvironments created by cancer. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1411-1425.	1.4	76
147	Differential Kinetics of Antigen Dependency of CD4+ and CD8+ T Cells. <i>Journal of Immunology</i> , 2014, 192, 3507-3517.	0.4	42
149	Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 1109-1124.	2.7	72
150	Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junction. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 1273-1284.	2.0	1
151	Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1769-1781.	1.4	4

#	ARTICLE	IF	CITATIONS
152	Chimeric DNA Vaccines: An Effective Way to Overcome Immune Tolerance. <i>Current Topics in Microbiology and Immunology</i> , 2014, 405, 99-122.	0.7	10
153	Myeloid-Derived Suppressor Cells Regulate Immune Response in Patients with Chronic Hepatitis B Virus Infection through PD-1-Induced IL-10. <i>Journal of Immunology</i> , 2014, 193, 5461-5469.	0.4	84
154	Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer. <i>Cancer Immunology Research</i> , 2014, 2, 133-141.	1.6	115
155	Aging, Immunosenescence, and Cancer. , 2014, , 55-69.		2
156	Myeloid-derived suppressor cell heterogeneity in human cancers. <i>Annals of the New York Academy of Sciences</i> , 2014, 1319, 47-65.	1.8	349
157	Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. , 2014, 2, 11.		173
158	Neoadjuvant anti-tumor vaccination prior to surgery enhances survival. <i>Journal of Translational Medicine</i> , 2014, 12, 245.	1.8	12
159	Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 545-557.	2.0	102
160	Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. , 2014, 2, 14.		108
161	Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines. <i>Cytotherapy</i> , 2014, 16, 427-439.	0.3	27
162	Myeloid-Derived Suppressor Cells in Cancer: Therapeutic, Predictive, and Prognostic Implications. <i>Seminars in Oncology</i> , 2014, 41, 174-184.	0.8	147
163	Therapeutic vaccines for cancer: an overview of clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 509-524.	12.5	636
164	A phase I study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). <i>Journal of Translational Medicine</i> , 2014, 12, 108.	1.8	75
165	Immune and Anticancer Responses Elicited by Fully Synthetic Aberrantly Glycosylated MUC1 Tripartite Vaccines Modified by a TLR2 or TLR9 Agonist. <i>ChemBioChem</i> , 2014, 15, 1508-1513.	1.3	60
166	High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine. <i>Vaccine</i> , 2014, 32, 5901-5907.	1.7	54
167	Tumor-Induced Immune Suppression. , 2014, , .		3
168	Landmarks in the diagnosis and treatment of renal cell carcinoma. <i>Nature Reviews Urology</i> , 2014, 11, 517-525.	1.9	176
169	Targeting CCR4 as an emerging strategy for cancer therapy and vaccines. <i>Trends in Pharmacological Sciences</i> , 2014, 35, 163-165.	4.0	36

#	ARTICLE	IF	CITATIONS
170	Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine. <i>Immunology Letters</i> , 2014, 161, 20-30.	1.1	24
171	Minimal changes in the systemic immune response after nephrectomy of localized renal masses ¹¹ This work was supported by the University of Iowa Carver College of Medicine/Department of Urology Investigator Start-up Funds, NIH Grant CA181088-01 (to L.A.N.), and NIH Grant CA109446 (to T.S.G.).. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 589-600.	0.8	19
172	HLA-Binding Properties of Tumor Neopeptides in Humans. <i>Cancer Immunology Research</i> , 2014, 2, 522-529.	1.6	194
173	A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 407-418.	2.0	82
174	A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs. <i>Therapeutic Advances in Vaccines</i> , 2014, 2, 10-31.	2.7	77
175	Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. <i>Haematologica</i> , 2014, 99, 1212-1219.	1.7	125
176	MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines. <i>Therapeutic Advances in Vaccines</i> , 2014, 2, 77-89.	2.7	101
177	Impaired NK cells and increased T regulatory cell numbers during cytotoxic maintenance therapy in AML. <i>Leukemia Research</i> , 2014, 38, 964-969.	0.4	34
178	CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. <i>Blood</i> , 2014, 124, 750-760.	0.6	206
179	Renal cell carcinoma: An update for the practicing urologist. <i>Asian Journal of Urology</i> , 2015, 2, 19-25.	0.5	10
180	Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. <i>Journal of Translational Medicine</i> , 2015, 13, 214.	1.8	84
181	2015 Guidance on cancer immunotherapy development in early-phase clinical studies. <i>Cancer Science</i> , 2015, 106, 1761-1771.	1.7	16
182	One decade of improving palliative care of metastatic renal cell carcinoma by antiangiogenic therapies: Time to move toward RCC cure. <i>International Journal of Cancer</i> , 2015, 136, 1483-1484.	2.3	1
183	Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses. <i>Cancer Science</i> , 2015, 106, 505-511.	1.7	40
184	New clinical advances in immunotherapy for the treatment of solid tumours. <i>Immunology</i> , 2015, 145, 182-201.	2.0	35
186	The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy. <i>Blood</i> , 2015, 126, 1203-1213.	0.6	103
187	Increase in Both CD14-Positive and CD15-Positive Myeloid-Derived Suppressor Cell Subpopulations in the Blood of Patients With Glioma But Predominance of CD15-Positive Myeloid-Derived Suppressor Cells in Glioma Tissue. <i>Journal of Neuropathology and Experimental Neurology</i> , 2015, 74, 390-400.	0.9	98
188	Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. <i>Journal of Immunotherapy</i> , 2015, 3, 26.		206

#	ARTICLE	IF	CITATIONS
189	Immune monitoring technology primer: the enzyme-linked immunospot (Elispot) and Fluorospot assay. , 2015, 3, 30.		9
190	Immunomodulatory Effects of Probiotic Supplementation in Schizophrenia Patients: A Randomized, Placebo-Controlled Trial. Biomarker Insights, 2015, 10, BML.S22007.	1.0	109
191	The Monocyte That Wasnâ€™t*. Critical Care Medicine, 2015, 43, 1532-1534.	0.4	1
192	Emerging Role for Novel Immunotherapy Agents in Metastatic Renal Cell Carcinoma: From Bench to Bedside. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e291-e297.	1.8	4
193	Therapeutic cancer vaccines. Journal of Clinical Investigation, 2015, 125, 3401-3412.	3.9	640
194	Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine. Vaccines, 2015, 3, 490-502.	2.1	43
195	Establishing the pig as a large animal model for vaccine development against human cancer. Frontiers in Genetics, 2015, 6, 286.	1.1	24
196	Automated, Miniaturized, and Integrated Quality Control-on-Chip (QC-on-a-Chip) for Cell-Based Cancer Therapy Applications. Frontiers in Materials, 2015, 2, .	1.2	22
197	Therapeutic strategy for cancer immunotherapy in head and neck cancer. Advances in Cellular and Molecular Otolaryngology, 2015, 3, 27690.	0.4	5
198	Oncogenic cancer/testis antigens: prime candidates for immunotherapy. Oncotarget, 2015, 6, 15772-15787.	0.8	265
199	Dendritic Cell-Based Vaccine Efficacy: Aiming for Hot Spots. Frontiers in Immunology, 2015, 6, 91.	2.2	59
200	Host-directed therapy: tuberculosis vaccine development. Lancet Respiratory Medicine,the, 2015, 3, 172-173.	5.2	1
201	Vaccines, Adjuvants, and Dendritic Cell Activatorsâ€™ Current Status and Future Challenges. Seminars in Oncology, 2015, 42, 549-561.	0.8	37
202	The role of active vaccination in cancer immunotherapy: lessons from clinical trials. Current Opinion in Immunology, 2015, 35, 15-22.	2.4	33
203	Cancer Vaccines. , 2015, , 365-388.		3
204	Could mycobacterial Hsp70-containing fusion protein lead the way to an affordable therapeutic cancer vaccine?. Expert Review of Vaccines, 2015, 14, 435-446.	2.0	7
205	Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2015, 21, 4224-4233.	3.2	33
206	Increased CCL17 serum levels are associated with improved survival in advanced melanoma. Cancer Immunology, Immunotherapy, 2015, 64, 1075-1082.	2.0	16

#	ARTICLE	IF	CITATIONS
207	Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry*. Molecular and Cellular Proteomics, 2015, 14, 3105-3117.	2.5	188
208	Insights on Peptide Vaccines in Cancer Immunotherapy. Cancer Drug Discovery and Development, 2015, , 1-27.	0.2	2
209	Complexity and challenges in defining myeloid-derived suppressor cells. , 2015, 88, 77-91.		119
210	TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity. Current Opinion in Immunology, 2015, 33, 16-22.	2.4	86
211	Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer. Clinical and Experimental Metastasis, 2015, 32, 111-124.	1.7	17
212	Mass Spectrometry of Human Leukocyte Antigen Class I Peptidomes Reveals Strong Effects of Protein Abundance and Turnover on Antigen Presentation. Molecular and Cellular Proteomics, 2015, 14, 658-673.	2.5	445
213	HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E166-75.	3.3	150
214	Inhibition of vascular endothelial growth factor by small interfering RNA upregulates differentiation, maturation and function of dendritic cells. Experimental and Therapeutic Medicine, 2015, 9, 120-124.	0.8	10
215	Synthetic Nanoparticles for Vaccines and Immunotherapy. Chemical Reviews, 2015, 115, 11109-11146.	23.0	623
216	Guidelines for the automated evaluation of Elispot assays. Nature Protocols, 2015, 10, 1098-1115.	5.5	74
217	Critical Roles of Chemoresistant Effector and Regulatory T Cells in Antitumor Immunity after Lymphodepleting Chemotherapy. Journal of Immunology, 2015, 195, 726-735.	0.4	24
218	Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunology, Immunotherapy, 2015, 64, 1271-1286.	2.0	161
219	Engineered materials for cancer immunotherapy. Nano Today, 2015, 10, 511-531.	6.2	96
220	Engineering New Approaches to Cancer Vaccines. Cancer Immunology Research, 2015, 3, 836-843.	1.6	50
222	Personalized immunotherapy (AGS-003) when combined with sunitinib for the treatment of metastatic renal cell carcinoma. Expert Opinion on Biological Therapy, 2015, 15, 1241-1248.	1.4	17
223	Cancer vaccines. BMJ, The, 2015, 350, h988-h988.	3.0	199
224	Peptide Immunotherapy in Vaccine Development. Advances in Protein Chemistry and Structural Biology, 2015, 99, 1-14.	1.0	31
225	Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters. Cancer Immunology, Immunotherapy, 2015, 64, 585-598.	2.0	18

#	ARTICLE	IF	CITATIONS
226	Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIX [®] vaccine in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 507-518.	2.0	31
227	Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report. <i>BMC Cancer</i> , 2015, 15, 58.	1.1	14
228	A combined approach of human leukocyte antigen ligandomics and immunogenicity analysis to improve peptide-based cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1295-1303.	2.0	10
229	The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies. <i>Cancer Immunology Research</i> , 2015, 3, 436-443.	1.6	631
230	Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 30-38.	3.2	158
231	Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy. <i>Clinical Cancer Research</i> , 2015, 21, 4073-4085.	3.2	97
232	Treg(s) in Cancer: Friends or Foe?. <i>Journal of Cellular Physiology</i> , 2015, 230, 2598-2605.	2.0	105
233	Immune evasion in cancer: Mechanistic basis and therapeutic strategies. <i>Seminars in Cancer Biology</i> , 2015, 35, S185-S198.	4.3	1,122
234	Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 485-493.	1.1	14
235	Immunologic Correlates in the Course of Treatment With Immunomodulating Antibodies. <i>Seminars in Oncology</i> , 2015, 42, 448-458.	0.8	22
236	Immune-mediated mechanisms influencing the efficacy of anticancer therapies. <i>Trends in Immunology</i> , 2015, 36, 198-216.	2.9	121
237	Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma. <i>Oncolmmunology</i> , 2015, 4, e1001236.	2.1	22
238	Checkpoint blockade in combination with cancer vaccines. <i>Vaccine</i> , 2015, 33, 7377-7385.	1.7	33
239	Expression of Cationic Amino Acid Transporter 2 Is Required for Myeloid-Derived Suppressor Cell ⁺ Mediated Control of T Cell Immunity. <i>Journal of Immunology</i> , 2015, 195, 5237-5250.	0.4	74
240	Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1609-1621.	2.0	42
241	Myeloid-derived suppressor cells in human peripheral blood: Optimized quantification in healthy donors and patients with metastatic renal cell carcinoma. <i>Immunology Letters</i> , 2015, 168, 260-267.	1.1	20
242	Analogue peptides for the immunotherapy of human acute myeloid leukemia. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1357-1367.	2.0	11
243	Nanomedicine and cancer immunotherapy ⁺ targeting immunosuppressive cells. <i>Journal of Drug Targeting</i> , 2015, 23, 656-671.	2.1	32

#	ARTICLE	IF	CITATIONS
244	Enhanced anti-colon cancer immune responses with modified eEF2-derived peptides. <i>Cancer Letters</i> , 2015, 369, 112-123.	3.2	10
245	Integrating Immunotherapies in Prostate Cancer. <i>Current Oncology Reports</i> , 2015, 17, 45.	1.8	3
246	Checkpoint modulation - A new way to direct the immune system against renal cell carcinoma. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1201-1208.	1.4	11
248	Engineering opportunities in cancer immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14467-14472.	3.3	111
249	Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry. <i>Molecular and Cellular Proteomics</i> , 2015, 14, 3105-3117.	2.5	107
250	Strategies for Improving Vaccines to Elicit T Cells to Treat Cancer. <i>Cancer Drug Discovery and Development</i> , 2015, , 29-52.	0.2	1
251	Active Immunotherapy of Cancer. <i>Immunological Investigations</i> , 2015, 44, 817-836.	1.0	41
253	Targeting the bone marrow microenvironment in multiple myeloma. <i>Immunological Reviews</i> , 2015, 263, 160-172.	2.8	323
254	Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy. <i>Leukemia</i> , 2015, 29, 647-659.	3.3	131
255	Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1-13.	2.0	104
256	Regulation of Tumor Metastasis by Myeloid-Derived Suppressor Cells. <i>Annual Review of Medicine</i> , 2015, 66, 97-110.	5.0	406
257	Cryopreservation of MHC multimers: Recommendations for quality assurance in detection of antigen specific T cells. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2015, 87, 37-48.	1.1	19
258	Manipulation of regulatory T cells and antigen-specific cytotoxic T lymphocyte-based tumour immunotherapy. <i>Immunology</i> , 2015, 144, 186-196.	2.0	36
259	Immunotherapy in Colorectal Cancer. , 2016, , .		0
260	Combining Immunotherapies with Standard Therapies in the Treatment of Cancer. , 2016, , 569-580.		0
261	Monitoring of the Immune Dysfunction in Cancer Patients. <i>Vaccines</i> , 2016, 4, 29.	2.1	15
262	Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors. <i>Vaccines</i> , 2016, 4, 37.	2.1	63
263	MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice. <i>PLoS ONE</i> , 2016, 11, e0145920.	1.1	31

#	ARTICLE	IF	CITATIONS
265	Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting. <i>Vaccines</i> , 2016, 4, 28.	2.1	372
266	Computational genomics tools for dissecting tumour-immune cell interactions. <i>Nature Reviews Genetics</i> , 2016, 17, 441-458.	7.7	233
267	Hepatitis C virus-induced myeloid-derived suppressor cells regulate T cell differentiation and function via the signal transducer and activator of transcription 3 pathway. <i>Immunology</i> , 2016, 148, 377-386.	2.0	47
268	Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient. <i>Journal of Hepatology</i> , 2016, 65, 849-855.	1.8	75
269	Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab. <i>Cytotherapy</i> , 2016, 18, 1043-1055.	0.3	45
270	Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design. <i>OncImmunity</i> , 2016, 5, e1204504.	2.1	19
271	Immunotherapy for genitourinary cancer. <i>Anti-Cancer Drugs</i> , 2016, 27, 585-599.	0.7	4
272	CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment. <i>OncImmunity</i> , 2016, 5, e1238541.	2.1	56
273	Validation of biomarkers to predict response to immunotherapy in cancer: Volume I pre-analytical and analytical validation. , 2016, 4, 76.		155
274	Biochemistry of Oxidative Stress. , 2016, , .		5
275	Tumor-Induced Myeloid-Derived Suppressor Cells. <i>Microbiology Spectrum</i> , 2016, 4, .	1.2	28
276	Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives. <i>European Journal of Cancer</i> , 2016, 59, 160-170.	1.3	78
277	Targeting regulatory T cells in tumors. <i>FEBS Journal</i> , 2016, 283, 2731-2748.	2.2	179
279	Neoadjuvant treatment for melanoma: current challenges and future perspectives. <i>Melanoma Management</i> , 2016, 3, 149-159.	0.1	1
280	The present status and future prospects of peptide-based cancer vaccines. <i>International Immunology</i> , 2016, 28, 319-328.	1.8	104
281	Pretreatment Immune Status Correlates with Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer Patients. <i>Cancer Immunology Research</i> , 2016, 4, 592-599.	1.6	56
282	Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors. <i>Clinical Immunology</i> , 2016, 166-167, 48-58.	1.4	45
283	Mass spectrometry-based antigen discovery for cancer immunotherapy. <i>Current Opinion in Immunology</i> , 2016, 41, 9-17.	2.4	165

#	ARTICLE	IF	CITATIONS
284	Old-School Chemotherapy in Immunotherapeutic Combination in Cancer, A Low-cost Drug Repurposed. <i>Cancer Immunology Research</i> , 2016, 4, 377-382.	1.6	43
285	HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy. <i>OncImmunology</i> , 2016, 5, e1065369.	2.1	18
286	Roles of regulatory T cells in cancer immunity. <i>International Immunology</i> , 2016, 28, 401-409.	1.8	412
287	Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes. <i>Clinical Cancer Research</i> , 2016, 22, 4827-4836.	3.2	24
288	Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016, 22, 4848-4858.	3.2	146
289	T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells. <i>Blood</i> , 2016, 128, 1081-1092.	0.6	120
290	Tumor antigen-specific T cells for immune monitoring of dendritic cell-treated glioblastoma patients. <i>Cytotherapy</i> , 2016, 18, 1146-1161.	0.3	6
291	Peripheral blood myeloid-derived suppressor cells reflect disease status in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2016, 48, 1171-1183.	3.1	55
292	Immunotherapy in atypical teratoid-rhabdoid tumors: Data from a survey of the HGG-Immuno Group. <i>Cytotherapy</i> , 2016, 18, 1178-1186.	0.3	18
293	Adjuvants for peptide-based cancer vaccines. , 2016, 4, 56.		126
295	Plasma Cell Dyscrasias. <i>Cancer Treatment and Research</i> , 2016, , .	0.2	3
296	Targeting the Bone Marrow Microenvironment. <i>Cancer Treatment and Research</i> , 2016, 169, 63-102.	0.2	12
297	IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1599-1611.	5.1	181
298	Vaccine therapy in renal cell carcinoma: attempting to leap over a rising bar. <i>Lancet Oncology</i> , The, 2016, 17, 1477-1478.	5.1	2
299	Immunotherapy of advanced renal cell carcinoma: Current and future therapies. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2997-3004.	1.4	12
300	Inhibition of mouse breast adenocarcinoma growth by ablation with intratumoral alpha-irradiation combined with inhibitors of immunosuppression and CpG. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1149-1158.	2.0	29
301	Improvement of anti-tumor immunity of fibroblast activation protein $\hat{\pm}$ based vaccines by combination with cyclophosphamide in a murine model of breast cancer. <i>Cellular Immunology</i> , 2016, 310, 89-98.	1.4	20
302	Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells. <i>Immunity</i> , 2016, 45, 1135-1147.	6.6	510

#	ARTICLE	IF	CITATIONS
303	The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat. <i>Oncolmmunology</i> , 2016, 5, e1219008.	2.1	58
304	The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 661-671.	1.1	297
305	MonoSeq Variant Caller Reveals Novel Mononucleotide Run Indel Mutations in Tumors with Defective DNA Mismatch Repair. <i>Human Mutation</i> , 2016, 37, 1004-1012.	1.1	6
306	Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses. <i>Science Translational Medicine</i> , 2016, 8, 334ra52.	5.8	164
307	Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. <i>Nature Communications</i> , 2016, 7, 12624.	5.8	550
308	Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab. <i>Oncolmmunology</i> , 2016, 5, e1249559.	2.1	51
309	Ontogeny of Tumor-associated CD4+CD25+Foxp3+ T-regulatory Cells. <i>Immunological Investigations</i> , 2016, 45, 729-745.	1.0	6
310	Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis. <i>BMC Medicine</i> , 2016, 14, 89.	2.3	57
311	Immunotherapy for Renal Cancer: Sequencing and Combinations. <i>European Urology Focus</i> , 2016, 2, 582-588.	1.6	5
312	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, December 5th 2015. , 2016, 4, .		0
313	Combining chemotherapy and immune checkpoint blockade. <i>Current Opinion in Urology</i> , 2016, 26, 508-513.	0.9	3
314	Advances in treatment of metastatic renal cell carcinoma. <i>Current Opinion in Urology</i> , 2016, 26, 439-446.	0.9	9
315	High-sensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patients' sera. <i>Proteomics</i> , 2016, 16, 1570-1580.	1.3	64
316	The 2nd meeting of the Campania Society of Oncology Immunotherapy (SCITO): focus on hepatocellular carcinoma, kidney and bladder cancer. , 2016, 4, .		18
317	Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. <i>Nature Reviews Urology</i> , 2016, 13, 420-431.	1.9	78
318	A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Muropeptide Therapeutic) Tj ETQq1 1 0.784314 rgBT /Overl	3.2	125
319	Immunotherapy in glioblastoma: emerging options in precision medicine. <i>CNS Oncology</i> , 2016, 5, 175-186.	1.2	11
320	Genomic determinants of cancer immunotherapy. <i>Current Opinion in Immunology</i> , 2016, 41, 32-38.	2.4	27

#	ARTICLE	IF	CITATIONS
321	Progress of dendritic cell-based cancer vaccines for patients with hematological malignancies. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1113-1123.	1.4	9
322	A clinical and biological perspective of human myeloid-derived suppressor cells in cancer. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 4043-4061.	2.4	55
323	SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade. <i>Oncolmunology</i> , 2016, 5, e1169353.	2.1	33
324	Improving cancer immunotherapy by targeting the STAtE of MDSCs. <i>Oncolmunology</i> , 2016, 5, e1196312.	2.1	50
325	Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 161-169.	2.0	175
326	Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. <i>Lancet Infectious Diseases</i> , The, 2016, 16, e47-e63.	4.6	265
327	<sc>RANK</sc> as a therapeutic target in cancer. <i>FEBS Journal</i> , 2016, 283, 2018-2033.	2.2	47
328	Natürliche Immunität und ihre Bedeutung für das Mikrobiom. , 2016, , 37-47.		0
329	The clinical and prognostic significance of CD14+HLA-DR ^{low} myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy. <i>Tumor Biology</i> , 2016, 37, 10427-10433.	0.8	66
330	Cancer vaccines: limited success but the research should remain viable. <i>Expert Review of Vaccines</i> , 2016, 15, 677-680.	2.0	5
331	Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response. <i>Clinical Cancer Research</i> , 2016, 22, 2342-2350.	3.2	132
332	Immunotherapy of Cancer. , 2016, , .		3
333	Expansion of myeloid-derived suppressor cells promotes differentiation of regulatory T cells in HIV-1+ individuals. <i>Aids</i> , 2016, 30, 1521-1531.	1.0	64
334	Peptide Vaccine. , 2016, , 135-142.		0
335	Dendritic Cell-Based Vaccine for Cancer. , 2016, , 197-220.		0
336	Vaccines for established cancer: overcoming the challenges posed by immune evasion. <i>Nature Reviews Cancer</i> , 2016, 16, 219-233.	12.8	580
337	Advances in Therapeutic Cancer Vaccines. <i>Advances in Immunology</i> , 2016, 130, 191-249.	1.1	88
338	Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy. <i>Oncolmunology</i> , 2016, 5, e1108511.	2.1	41

#	ARTICLE	IF	CITATIONS
339	MDSCs in cancer: Conceiving new prognostic and therapeutic targets. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 35-48.	3.3	68
340	Novel Treatments in Development for Melanoma. <i>Cancer Treatment and Research</i> , 2016, 167, 371-416.	0.2	15
341	Cancer Neoantigens and Applications for Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 807-812.	3.2	188
342	Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma. <i>Oncolmmunology</i> , 2016, 5, e1105429.	2.1	70
343	Personalized approaches to active immunotherapy in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 72-82.	3.3	41
344	Antitumor dendritic cell-based vaccines: lessons from 20 years of clinical trials and future perspectives. <i>Translational Research</i> , 2016, 168, 74-95.	2.2	116
345	Developments in cancer vaccines for hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 93-99.	2.0	55
346	The diversity of circulating neutrophils in cancer. <i>Immunobiology</i> , 2017, 222, 82-88.	0.8	109
347	Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. <i>Immunity</i> , 2017, 46, 197-204.	6.6	400
348	Low CCL17 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma. <i>BMC Cancer</i> , 2017, 17, 117.	1.1	6
351	Identification of Immunogenic Epitopes by MS/MS. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 102-107.	1.0	19
352	Effects of combined epidural and general anesthesia on intraoperative hemodynamic responses, postoperative cellular immunity, and prognosis in patients with gallbladder cancer. <i>Medicine (United Tj ETQq1 1 0784314 rgBT /Ove</i>		
353	Immunotherapy for metastatic renal cell carcinoma. <i>The Cochrane Library</i> , 2017, 2017, CD011673.	1.5	31
354	Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 287-298.	1.4	4
355	Metastasized murine oral squamous cell carcinoma cells induce intratumoral polymorphonuclear myeloid derived suppressor cells. <i>Oncology Reports</i> , 2017, 37, 2897-2904.	1.2	6
356	Trends in Scientific Discovery. , 2017, , 31-64.		0
357	Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects <i>in vivo</i> . <i>Oncolmmunology</i> , 2017, 6, e1323161.	2.1	39
358	A novel <i>in silico</i> framework to improve MHC-I epitopes and break the tolerance to melanoma. <i>Oncolmmunology</i> , 2017, 6, e1319028.	2.1	25

#	ARTICLE	IF	CITATIONS
359	Peptide Vaccine: Overview. , 2017, , 427-439.		1
360	Evolving adoptive cellular therapies in urological malignancies. <i>Lancet Oncology</i> , The, 2017, 18, e341-e353.	5.1	22
361	Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). <i>Clinical Cancer Research</i> , 2017, 23, 5034-5043.	3.2	34
362	Personalized peptide vaccines and their relation to other therapies in urological cancer. <i>Nature Reviews Urology</i> , 2017, 14, 501-510.	1.9	30
363	The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancer. <i>British Journal of Haematology</i> , 2017, 179, 20-35.	1.2	77
364	A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer. <i>Cancer Science</i> , 2017, 108, 838-845.	1.7	30
365	PSSMHCpan: a novel PSSM-based software for predicting class I peptide-HLA binding affinity. <i>GigaScience</i> , 2017, 6, 1-11.	3.3	67
366	Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens. <i>Acta Neuropathologica</i> , 2017, 134, 297-316.	3.9	23
367	Systematic evaluation of immune regulation and modulation. , 2017, 5, 21.		20
368	Dynamic and specific immune responses against multiple tumor antigens were elicited in patients with hepatocellular carcinoma after cell-based immunotherapy. <i>Journal of Translational Medicine</i> , 2017, 15, 64.	1.8	15
369	Near-Infrared-Triggered Photodynamic Therapy with Multitasking Upconversion Nanoparticles in Combination with Checkpoint Blockade for Immunotherapy of Colorectal Cancer. <i>ACS Nano</i> , 2017, 11, 4463-4474.	7.3	583
370	Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIC2) in patients with metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 17-24.	2.0	12
371	A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder. <i>Annals of Oncology</i> , 2017, 28, 798-803.	0.6	43
372	Cyclophosphamide enhances anti-tumor effects of a fibroblast activation protein β -based DNA vaccine in tumor-bearing mice with murine breast carcinoma. <i>Immunopharmacology and Immunotoxicology</i> , 2017, 39, 37-44.	1.1	31
373	HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy. <i>Oncolimmunology</i> , 2017, 6, e1219825.	2.1	28
374	Establishing High Dimensional Immune Signatures from Peripheral Blood via Mass Cytometry in a Discovery Cohort of Stage IV Melanoma Patients. <i>Journal of Immunology</i> , 2017, 198, 927-936.	0.4	33
375	Immuno-oncology for renal cell carcinoma treatment: future perspectives for combinations and sequences with molecularly targeted agents. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 151-162.	1.4	4
376	Treatment of renal cell carcinoma: Current status and future directions. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 507-524.	157.7	583

#	ARTICLE	IF	CITATIONS
377	Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. <i>Immunological Reviews</i> , 2017, 280, 165-174.	2.8	82
378	Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects. <i>Drug Resistance Updates</i> , 2017, 32, 1-15.	6.5	132
380	Encapsulation of Hydrophilic and Hydrophobic Peptides into Hollow Mesoporous Silica Nanoparticles for Enhancement of Antitumor Immune Response. <i>Small</i> , 2017, 13, 1701741.	5.2	55
381	Surface-Engineered Red Blood Cells as Artificial Antigen Presenting Cells Promising for Cancer Immunotherapy. <i>Small</i> , 2017, 13, 1701864.	5.2	56
382	Regulatory T Cells: Molecular and Cellular Basis for Immunoregulation. <i>Current Topics in Microbiology and Immunology</i> , 2017, 410, 3-27.	0.7	48
383	Emerging immunotherapy in advanced renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 687-693.	0.8	14
384	A novel immunization approach for dengue infection based on conserved T cell epitopes formulated in calcium phosphate nanoparticles. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2612-2625.	1.4	13
385	Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, which Associate with Survival in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6771-6780.	3.2	114
386	Secreted Tumor Antigens – Immune Biomarkers for Diagnosis and Therapy. <i>Proteomics</i> , 2017, 17, 1600442.	1.3	27
387	Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot. <i>European Journal of Pediatrics</i> , 2017, 176, 1163-1172.	1.3	11
388	Personalized peptide vaccines for cancer therapy: current progress and state of the art. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 371-381.	0.4	9
389	The immunopeptidomic landscape of ovarian carcinomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E9942-E9951.	3.3	152
391	Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells. <i>Oncolimmunology</i> , 2017, 6, e1331807.	2.1	106
392	Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 831-840.	0.8	14
393	Immunotherapy biomarkers 2016: overcoming the barriers. , 2017, 5, 29.		21
394	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. , 2017, 5, 44.		181
395	New vaccination strategies in liver cancer. <i>Cytokine and Growth Factor Reviews</i> , 2017, 36, 125-129.	3.2	20
396	Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior T cell responses and virus protection. <i>Journal of Dermatological Science</i> , 2017, 87, 252-259.	1.0	22

#	ARTICLE	IF	CITATIONS
397	The importance of correctly timing cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 87-103.	1.4	26
398	Immunosuppressive CD14 ⁺ HLA-DR ^{lo/neg} monocytes are elevated in pancreatic cancer and are primed by tumor-derived exosomes. <i>OncImmunity</i> , 2017, 6, e1252013.	2.1	59
399	Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients. <i>International Journal of Cancer</i> , 2017, 140, 973-982.	2.3	60
400	Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1 β , IL8, CXCL5, and Mip-1 α . <i>Clinical Cancer Research</i> , 2017, 23, 2346-2355.	3.2	148
401	Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	139
402	Preclinical and clinical development of neoantigen vaccines. <i>Annals of Oncology</i> , 2017, 28, xii11-xii17.	0.6	160
403	Multiple Myeloma and the immune microenvironment. <i>Current Cancer Drug Targets</i> , 2017, 17, 1-1.	0.8	59
405	AGS-003 combined with sunitinib for the precision treatment of metastatic renal cell carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 243-248.	0.4	0
406	Novel immunotherapy in metastatic renal cell carcinoma. <i>Investigative and Clinical Urology</i> , 2017, 58, 220.	1.0	16
407	The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 650.	1.8	20
408	Tumor abolition and antitumor immunostimulation by physico-chemical tumor ablation. <i>Frontiers in Bioscience - Landmark</i> , 2017, 22, 310-347.	3.0	38
409	"Hotspots" of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization. <i>Frontiers in Immunology</i> , 2017, 8, 1367.	2.2	133
410	Tertiary Lymphoid Structures in Cancer: Drivers of Antitumor Immunity, Immunosuppression, or Bystander Sentinels in Disease?. <i>Frontiers in Immunology</i> , 2017, 8, 1830.	2.2	168
411	MAGE-A Antigens and Cancer Immunotherapy. <i>Frontiers in Medicine</i> , 2017, 4, 18.	1.2	54
412	The current status of immunobased therapies for metastatic renal-cell carcinoma. <i>ImmunoTargets and Therapy</i> , 2017, Volume 6, 83-93.	2.7	14
413	Identification of patient-specific and tumor-shared T cell receptor sequences in renal cell carcinoma patients. <i>Oncotarget</i> , 2017, 8, 21212-21228.	0.8	10
414	Overexpression of Kinesin Family Member 20A Correlates with Disease Progression and Poor Prognosis in Human Nasopharyngeal Cancer: A Retrospective Analysis of 105 Patients. <i>PLoS ONE</i> , 2017, 12, e0169280.	1.1	32
415	Adoptive T-Cell Therapy for Solid Tumors. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 193-204.	1.8	44

#	ARTICLE	IF	CITATIONS
416	On the origin of myeloid-derived suppressor cells. <i>Oncotarget</i> , 2017, 8, 3649-3665.	0.8	156
417	Therapeutic Sequencing in Metastatic Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2017, 1, 15-29.	0.2	4
418	Adoptive T-Cell Therapy for Solid Tumors. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 193-204.	1.8	61
419	Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors. <i>Oncotarget</i> , 2017, 8, 53730-53739.	0.8	24
420	Tâ€œcell modulation by cyclophosphamide for tumour therapy. <i>Immunology</i> , 2018, 154, 62-68.	2.0	53
421	Mass Spectrometry Based Immunopeptidomics for the Discovery of Cancer Neoantigens. <i>Methods in Molecular Biology</i> , 2018, 1719, 209-221.	0.4	46
422	Peptidomics. <i>Methods in Molecular Biology</i> , 2018, , .	0.4	5
423	Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry. <i>Immunology</i> , 2018, 154, 331-345.	2.0	101
424	Cytotoxic T lymphocyte response to peptide vaccination predicts survival in stage <scp>III</scp> colorectal cancer. <i>Cancer Science</i> , 2018, 109, 1545-1551.	1.7	16
425	Peptide Vaccine Formulation Controls the Duration of Antigen Presentation and Magnitude of Tumor-Specific CD8+ T Cell Response. <i>Journal of Immunology</i> , 2018, 200, 3464-3474.	0.4	16
426	Personalized cancer vaccines: adjuvants are important, too. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1911-1918.	2.0	44
427	Present status and future perspective of peptideâ€œbased vaccine therapy for urological cancer. <i>Cancer Science</i> , 2018, 109, 550-559.	1.7	42
428	MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection. <i>Journal of Proteomics</i> , 2018, 176, 13-23.	1.2	27
429	Therapeutic cancer vaccines: From initial findings to prospects. <i>Immunology Letters</i> , 2018, 196, 11-21.	1.1	75
430	Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer. <i>Journal of Bone Oncology</i> , 2018, 11, 27-32.	1.0	63
431	Regulation of chitinase-3-like-1 in T cell elicits Th1 and cytotoxic responses to inhibit lung metastasis. <i>Nature Communications</i> , 2018, 9, 503.	5.8	72
433	Strategies to Reduce Intratumoral Regulatory T Cells. , 2018, , 483-506.		1
434	Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome?. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a028837.	2.3	7

#	ARTICLE	IF	CITATIONS
435	Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy. <i>Seminars in Cancer Biology</i> , 2018, 52, 26-38.	4.3	49
436	Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome?. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a028829.	2.3	40
437	Correlates of immune and clinical activity of novel cancer vaccines. <i>Seminars in Immunology</i> , 2018, 39, 119-136.	2.7	54
438	Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. <i>Clinical Cancer Research</i> , 2018, 24, 3014-3025.	3.2	64
439	Immune checkpoint blockade therapy. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1403-1414.	1.5	79
440	Validation of Immunomonitoring Methods for Application in Clinical Studies: The HLAâ€Peptide Multimer Staining Assay. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 342-353.	0.7	12
441	HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy. <i>Onc Immunology</i> , 2018, 7, e1316438.	2.1	42
442	Myeloidâ€derived suppressor cells: Important contributors to tumor progression and metastasis. <i>Journal of Cellular Physiology</i> , 2018, 233, 3024-3036.	2.0	141
443	Single Dose of Protein Vaccine with Peptide Nanofibers As Adjuvants Elicits Long-Lasting Antibody Titer. <i>ACS Biomaterials Science and Engineering</i> , 2018, 4, 2000-2006.	2.6	23
444	Immunotherapy for Pediatric Malignancies. , 2018, , .		0
445	Towards personalized, tumour-specific, therapeutic vaccines for cancer. <i>Nature Reviews Immunology</i> , 2018, 18, 168-182.	10.6	736
446	Allogeneic Stem Cell Transplantation. , 2018, , 39-64.		1
447	Co-delivery of human cancer-testis antigens with adjuvant in protein nanoparticles induces higher cell-mediated immune responses. <i>Biomaterials</i> , 2018, 156, 194-203.	5.7	48
448	Immunotherapy for kidney cancer. <i>Current Opinion in Urology</i> , 2018, 28, 8-14.	0.9	37
449	Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 57-67.	1.1	15
450	The Immunobiology of Kidney Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 3547-3552.	0.8	51
451	Cancer Vaccines: Dendritic Cell-Based Vaccines and Related Approaches. , 2018, , 260-260.		0
452	Tumor size and lymph node metastasis are prognostic markers of small cell lung cancer in a Chinese population. <i>Medicine (United States)</i> , 2018, 97, e11712.	0.4	16

#	ARTICLE	IF	CITATIONS
453	Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses. <i>Oncolmunology</i> , 2018, 7, e1500671.	2.1	31
454	CD33/CD3-bispecific T-cell engaging (BiTE [®]) antibody construct targets monocytic AML myeloid-derived suppressor cells. , 2018, 6, 116.		61
455	Induction of immunosuppressive functions and NF- κ B by FLIP in monocytes. <i>Nature Communications</i> , 2018, 9, 5193.	5.8	45
456	RNA editing derived epitopes function as cancer antigens to elicit immune responses. <i>Nature Communications</i> , 2018, 9, 3919.	5.8	120
458	Overexpression of kinesin family member 20A is associated with unfavorable clinical outcome and tumor progression in epithelial ovarian cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 3433-3450.	0.9	22
459	Trial watch: Peptide-based vaccines in anticancer therapy. <i>Oncolmunology</i> , 2018, 7, e1511506.	2.1	121
460	Pediatric Cancer Immunotherapy: Opportunities and Challenges. <i>Paediatric Drugs</i> , 2018, 20, 395-408.	1.3	76
461	Cancer Vaccines. , 2018, , 161-184.e6.		2
462	Blood-based analyses of cancer: Circulating myeloid-derived suppressor cells “ is a new era coming?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2018, 55, 376-407.	2.7	16
463	Cancer testis antigens as immunogenic and oncogenic targets in breast cancer. <i>Immunotherapy</i> , 2018, 10, 769-778.	1.0	31
464	Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies: A meta-analysis of 40 studies. <i>Oncolmunology</i> , 2018, 7, e1494113.	2.1	83
465	Development of Peptide Vaccines in Dengue. <i>Current Pharmaceutical Design</i> , 2018, 24, 1157-1173.	0.9	24
466	High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with Treg depletion. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1545-1558.	2.0	13
467	Regulatory T Cells As Potential Targets for HIV Cure Research. <i>Frontiers in Immunology</i> , 2018, 9, 734.	2.2	51
468	Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy. <i>Annals of Gastroenterological Surgery</i> , 2018, 2, 289-303.	1.2	35
469	Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 1499.	2.2	119
471	Therapeutic Vaccines for Genitourinary Malignancies. <i>Vaccines</i> , 2018, 6, 55.	2.1	9
472	Next Generation Cancer Vaccines“Make It Personal!. <i>Vaccines</i> , 2018, 6, 52.	2.1	20

#	ARTICLE	IF	CITATIONS
473	SPIRIT: A seamless phase I/II randomized design for immunotherapy trials. <i>Pharmaceutical Statistics</i> , 2018, 17, 527-540.	0.7	10
474	Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? <i>The GIANUS Review. Critical Reviews in Oncology/Hematology</i> , 2019, 139, 149-157.	2.0	10
475	Myeloid-derived suppressor cells: Roles in the tumor microenvironment and tumor radiotherapy. <i>International Journal of Cancer</i> , 2019, 144, 933-946.	2.3	67
476	Apolipoprotein A-I (ApoA-I), Immunity, Inflammation and Cancer. <i>Cancers</i> , 2019, 11, 1097.	1.7	127
477	Reprogramming lymphocytes for the treatment of melanoma: From biology to therapy. <i>Advanced Drug Delivery Reviews</i> , 2019, 141, 104-124.	6.6	14
478	Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy. <i>Biomedicine and Pharmacotherapy</i> , 2019, 120, 109542.	2.5	39
479	Recent advances in nanotheranostics for triple negative breast cancer treatment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 430.	3.5	121
480	A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. , 2019, 7, 307.		39
481	Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial. <i>Cancer Science</i> , 2019, 110, 3049-3060.	1.7	20
482	The Endless Saga of Monocyte Diversity. <i>Frontiers in Immunology</i> , 2019, 10, 1786.	2.2	67
483	Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. , 2019, 7, 255.		123
484	Immune Checkpoint Blockade. <i>Methods in Molecular Biology</i> , 2019, , .	0.4	0
485	Regulatory T cells in cancer immunosuppression – implications for anticancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 356-371.	12.5	872
486	Multifunctional polymeric micelle-based chemo-immunotherapy with immune checkpoint blockade for efficient treatment of orthotopic and metastatic breast cancer. <i>Acta Pharmaceutica Sinica B</i> , 2019, 9, 819-831.	5.7	43
487	Expansion and Determination of Antigen-Reactive T Cells by Flow Cytometry. <i>Methods in Molecular Biology</i> , 2019, 1913, 141-151.	0.4	2
488	Expression of costimulatory and inhibitory receptors in FoxP3+ regulatory T cells within the tumor microenvironment: Implications for combination immunotherapy approaches. <i>Advances in Cancer Research</i> , 2019, 144, 193-261.	1.9	19
489	Precision Medicine in Cancer Therapy. <i>Cancer Treatment and Research</i> , 2019, , .	0.2	4
490	Key Features Relevant to Select Antigens and TCR From the MHC-Mismatched Repertoire to Treat Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1485.	2.2	8

#	ARTICLE	IF	CITATIONS
491	Precision Medicine-Enabled Cancer Immunotherapy. <i>Cancer Treatment and Research</i> , 2019, 178, 189-205.	0.2	9
492	The CD14+HLA-DRlo/neg Monocyte: An Immunosuppressive Phenotype That Restrains Responses to Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 1147.	2.2	105
493	ACME: pan-specific peptide-MHC class I binding prediction through attention-based deep neural networks. <i>Bioinformatics</i> , 2019, 35, 4946-4954.	1.8	79
494	CD20-Mimotope Peptides: A Model to Define the Molecular Basis of Epitope Spreading. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1920.	1.8	8
496	Multiple antigen-engineered DC vaccines with or without IFN- γ to promote antitumor immunity in melanoma. , 2019, 7, 113.		31
497	Synergistic STING activation by PC7A nanovaccine and ionizing radiation improves cancer immunotherapy. <i>Journal of Controlled Release</i> , 2019, 300, 154-160.	4.8	61
498	Autologous tumor cell vaccination combined with systemic CpG-B and IFN- γ promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1025-1035.	2.0	13
499	Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy. <i>Immunotherapy</i> , 2019, 11, 515-529.	1.0	17
500	Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial. <i>Blood Cancer Journal</i> , 2019, 9, 45.	2.8	7
501	Immunotherapy for High-Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons. <i>World Neurosurgery</i> , 2019, 124, 397-409.	0.7	19
502	Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade. <i>Frontiers in Immunology</i> , 2019, 10, 467.	2.2	122
503	Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients. <i>Neuro-Oncology</i> , 2019, 21, 923-933.	0.6	89
504	Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System. <i>Journal of Oncology</i> , 2019, 2019, 1-18.	0.6	76
505	Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 787-798.	2.0	2
506	A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 799-812.	2.0	115
508	Cancer Vaccines. , 2019, , .		1
509	Murine xenograft bioreactors for human immunopeptidome discovery. <i>Scientific Reports</i> , 2019, 9, 18558.	1.6	9
510	Allies or Enemies-The Multifaceted Role of Myeloid Cells in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2019, 10, 2746.	2.2	41

#	ARTICLE	IF	CITATIONS
511	Melanoma vaccines: clinical status and immune endpoints. <i>Melanoma Research</i> , 2019, 29, 109-118.	0.6	19
512	Maintenance Therapy in Metastatic Solid Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 615-623.	0.6	4
513	Actively personalized vaccination trial for newly diagnosed glioblastoma. <i>Nature</i> , 2019, 565, 240-245.	13.7	637
514	Combination Therapy. , 2019, , 161-170.		0
515	Teaching an old dog new tricks: next-generation CAR T cells. <i>British Journal of Cancer</i> , 2019, 120, 26-37.	2.9	240
516	Neopeptides-based vaccines: challenges and perspectives. <i>European Journal of Cancer</i> , 2019, 108, 55-60.	1.3	20
517	Dendritic Cells in Hematopoietic Cell Transplantation. <i>Advances and Controversies in Hematopoietic Transplantation and Cell Therapy</i> , 2019, , 201-218.	0.0	0
518	Results of a Phase 1/2 Study in Metastatic Renal Cell Carcinoma Patients Treated with a Patient-specific Adjuvant Multi-peptide Vaccine after Resection of Metastases. <i>European Urology Focus</i> , 2019, 5, 604-607.	1.6	17
519	Immunity, Hypoxia, and Metabolism—the “Trois” of Cancer: Implications for Immunotherapy. <i>Physiological Reviews</i> , 2020, 100, 1-102.	13.1	190
520	At the bench: Engineering the next generation of cancer vaccines. <i>Journal of Leukocyte Biology</i> , 2020, 108, 1435-1453.	1.5	22
521	The tumor organismal environment: Role in tumor development and cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2020, 65, 197-206.	4.3	26
522	Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 383-397.	2.0	17
523	Exploring Essential Issues for Improving Therapeutic Cancer Vaccine Trial Design. <i>Cancers</i> , 2020, 12, 2908.	1.7	8
524	Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth. <i>Translational Oncology</i> , 2020, 13, 100856.	1.7	9
525	Immunotherapy for Renal Cell Carcinoma. , 0, , .		0
526	Immunotherapies and Combination Strategies for Immuno-Oncology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5009.	1.8	63
527	Dual-Antigen-Loaded Hepatitis B Virus Core Antigen Virus-like Particles Stimulate Efficient Immunotherapy Against Melanoma. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 53682-53690.	4.0	20
528	Circular RNA circ_001842 plays an oncogenic role in renal cell carcinoma by disrupting microRNA-mediated inhibition of SLC39A14. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 9712-9725.	1.6	21

#	ARTICLE	IF	CITATIONS
529	Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning. , 2020, 8, e000981.		15
530	Effective combinations of radiotherapy and immunotherapy in the treatment of esophageal squamous cell carcinoma. <i>Future Oncology</i> , 2020, 16, 2537-2549.	1.1	9
533	BILITE: A Bayesian randomized phase II design for immunotherapy by jointly modeling the longitudinal immune response and time-to-event efficacy. <i>Statistics in Medicine</i> , 2020, 39, 4439-4451.	0.8	2
534	Doxorubicin pretreatment enhances FAP ⁺ /survivin co-targeting DNA vaccine anti-tumor activity primarily through decreasing peripheral MDSCs in the 4T1 murine breast cancer model. <i>OncolImmunology</i> , 2020, 9, 1747350.	2.1	22
535	Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 595-610.	12.5	124
537	Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside. <i>Journal of Leukocyte Biology</i> , 2020, 108, 1455-1489.	1.5	22
538	Impact of Radiochemotherapy on Immune Cell Subtypes in High-Grade Glioma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 89.	1.3	14
539	Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma. <i>Drugs</i> , 2020, 80, 1169-1181.	4.9	53
540	mTORC1-dependent protein synthesis and autophagy uncouple in the regulation of Apolipoprotein A-I expression. <i>Metabolism: Clinical and Experimental</i> , 2020, 105, 154186.	1.5	11
541	Recent advancement and future perspective for the treatment of multidrug-resistant tuberculosis. , 2020, , 231-250.		1
542	Intratumoral immune activation with TLR4 agonist synergizes with effector T cells to eradicate established murine tumors. <i>Npj Vaccines</i> , 2020, 5, 50.	2.9	19
543	CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. <i>Nature Immunology</i> , 2020, 21, 298-308.	7.0	326
544	Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1375-1387.	2.0	75
545	Progress and challenges of personalized neoantigens in the clinical treatment of tumors. <i>Medicine in Drug Discovery</i> , 2020, 6, 100030.	2.3	3
546	Guidance Document: Validation of a High-Performance Liquid Chromatography-Tandem Mass Spectrometry Immunopeptidomics Assay for the Identification of HLA Class I Ligands Suitable for Pharmaceutical Therapies. <i>Molecular and Cellular Proteomics</i> , 2020, 19, 432-443.	2.5	31
547	Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy. <i>Genome Medicine</i> , 2020, 12, 32.	3.6	32
548	Identification of an immunogenic DKK1 long peptide for immunotherapy of human multiple myeloma. <i>Haematologica</i> , 2021, 106, 838-846.	1.7	6
549	Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome. <i>Journal of Proteome Research</i> , 2021, 20, 289-304.	1.8	32

#	ARTICLE	IF	CITATIONS
550	The Peptide Vaccine of the Future. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100022.	2.5	94
551	CIITA-Transduced Glioblastoma Cells Uncover a Rich Repertoire of Clinically Relevant Tumor-Associated HLA-II Antigens. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100032.	2.5	22
552	Monocytes in the Tumor Microenvironment. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2021, 16, 93-122.	9.6	126
553	Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development. <i>Cancer Biology and Medicine</i> , 2021, 18, 352-371.	1.4	22
554	Immunochemo combination therapy in cancer treatment. , 2021, , 255-273.		0
555	Sensitive Immunopeptidomics by Leveraging Available Large-Scale Multi-HLA Spectral Libraries, Data-Independent Acquisition, and MS/MS Prediction. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100080.	2.5	49
556	Hypofractionated Low-Dose Radiotherapy Combined with Immune Checkpoint Inhibition in Metastatic Solid Tumors. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 773-783.	1.0	2
557	Tumor Heterogeneity: A Great Barrier in the Age of Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 806.	1.7	67
558	The Potential Regulatory Roles of Circular RNAs in Tumor Immunology and Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 617583.	2.2	20
559	CTHRC1 Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Kidney Renal Papillary Cell Carcinoma and Kidney Renal Clear Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 570819.	1.3	13
560	Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments. <i>Frontiers in Immunology</i> , 2020, 11, 615240.	2.2	59
561	Current Advance of Immune Evasion Mechanisms and Emerging Immunotherapies in Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 639636.	2.2	33
562	Co-delivery of PSMA antigen epitope and mGM-CSF with a cholera toxin-like chimeric protein suppressed prostate tumor growth via activating dendritic cells and promoting CTL responses. <i>Vaccine</i> , 2021, 39, 1609-1620.	1.7	4
563	Targeting macrophages in cancer immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 127.	7.1	300
564	Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 653358.	2.2	19
565	Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1882-1896.	1.4	10
566	Renal cell carcinoma pathology in 2021: â€˜new need for renal cancer immune profilingâ€™. <i>Current Opinion in Urology</i> , 2021, 31, 228-235.	0.9	5
567	Therapeutic applications of the cancer immunoediting hypothesis. <i>Seminars in Cancer Biology</i> , 2022, 78, 63-77.	4.3	29

#	ARTICLE	IF	CITATIONS
568	Towards customized cancer vaccines: a promising field in personalized cancer medicine. <i>Expert Review of Vaccines</i> , 2021, 20, 545-557.	2.0	2
569	Tumor-related stress regulates functional plasticity of MDSCs. <i>Cellular Immunology</i> , 2021, 363, 104312.	1.4	10
570	Perspectives on passive antibody therapy and peptide-based vaccines against emerging pathogens like SARS-CoV-2. <i>Germs</i> , 2021, 11, 287-305.	0.5	2
571	Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities. <i>Vaccines</i> , 2021, 9, 623.	2.1	17
572	Therapeutic Cancer Vaccination with Immunopeptidomics-Discovered Antigens Confers Protective Antitumor Efficacy. <i>Cancers</i> , 2021, 13, 3408.	1.7	16
573	A purified acidic polysaccharide from <i>Sarcandra glabra</i> as vaccine adjuvant to enhance anti-tumor effect of cancer vaccine. <i>Carbohydrate Polymers</i> , 2021, 263, 117967.	5.1	10
574	Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia. <i>Frontiers in Immunology</i> , 2021, 12, 705974.	2.2	22
575	The role of immunogenic cell death in gastrointestinal cancer immunotherapy (Review). <i>Biomedical Reports</i> , 2021, 15, 86.	0.9	1
576	Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3679-3692.	2.0	15
577	Tumor-infiltrating CD8+ T cells recognize a heterogeneously expressed functional neoantigen in clear cell renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 905-918.	2.0	8
578	A novel era of cancer/testis antigen in cancer immunotherapy. <i>International Immunopharmacology</i> , 2021, 98, 107889.	1.7	36
579	Beyond conventional immune-checkpoint inhibition – novel immunotherapies for renal cell carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 199-214.	12.5	179
580	Future of Cancer Vaccines. <i>Methods in Molecular Biology</i> , 2014, 1139, 555-564.	0.4	8
581	Current Landscape of Immunotherapy in Genitourinary Malignancies. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 107-147.	0.8	3
582	B Cells in the Gastrointestinal Tumor Microenvironment with a Focus on Pancreatic Cancer: Opportunities for Precision Medicine?. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1273, 175-195.	0.8	2
583	From Basic Immunology to New Therapies for Cancer Patients. , 2014, , 3-11.		3
584	Vaccine Approaches in Hepatocellular Carcinoma. , 2017, , 1-17.		1
585	TRICOM Poxviral-Based Vaccines for the Treatment of Cancer. , 2014, , 291-327.		1

#	ARTICLE	IF	CITATIONS
586	Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma. <i>HemaSphere</i> , 2020, 4, e350.	1.2	29
588	Efficacy of the NCCV Cocktail vaccine for refractory pediatric solid tumors: A phase I clinical trial. <i>Cancer Science</i> , 2019, 110, 3650-3662.	1.7	8
589	Tumor-Induced Myeloid-Derived Suppressor Cells. , 0, , 833-856.		1
590	IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. <i>Journal of Clinical Investigation</i> , 2013, 123, 3383-3394.	3.9	137
591	Radiation and immunotherapy: a synergistic combination. <i>Journal of Clinical Investigation</i> , 2013, 123, 2756-2763.	3.9	226
592	Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. <i>Journal of Clinical Investigation</i> , 2015, 125, 3365-3376.	3.9	443
593	Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. <i>Journal of Clinical Investigation</i> , 2018, 128, 5505-5516.	3.9	193
594	Therapeutic Vaccines and Immunotherapy in Castration-Resistant Prostate Cancer: Current Progress and Clinical Applications. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e166-e170.	1.8	13
595	Strategies for developing and optimizing cancer vaccines. <i>F1000Research</i> , 2019, 8, 654.	0.8	43
596	Fusion Protein Vaccines Targeting Two Tumor Antigens Generate Synergistic Anti-Tumor Effects. <i>PLoS ONE</i> , 2013, 8, e71216.	1.1	4
597	Human CD4+CD25+ Regulatory T Cells Are Sensitive to Low Dose Cyclophosphamide: Implications for the Immune Response. <i>PLoS ONE</i> , 2013, 8, e83384.	1.1	80
598	Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab. <i>PLoS ONE</i> , 2014, 9, e87705.	1.1	261
599	Efficacy of Imiquimod-Based Transcutaneous Immunization Using a Nano-Dispersed Emulsion Gel Formulation. <i>PLoS ONE</i> , 2014, 9, e102664.	1.1	37
600	Obesity Triggers Enhanced MDSC Accumulation in Murine Renal Tumors via Elevated Local Production of CCL2. <i>PLoS ONE</i> , 2015, 10, e0118784.	1.1	62
601	The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function. <i>PLoS ONE</i> , 2015, 10, e0128897.	1.1	25
602	Pre-Vaccination Frequencies of Th17 Cells Correlate with Vaccine-Induced T-Cell Responses to Survivin-Derived Peptide Epitopes. <i>PLoS ONE</i> , 2015, 10, e0131934.	1.1	11
603	Regulatory T Cells in Endemic Burkitt Lymphoma Patients Are Associated with Poor Outcomes: A Prospective, Longitudinal Study. <i>PLoS ONE</i> , 2016, 11, e0167841.	1.1	14
604	Present and future perspectives on immunotherapy for advanced renal cell carcinoma: Going to the core or beating around the bush?. <i>Journal of Kidney Cancer and VHL</i> , 2015, 2, 55-63.	0.2	3

#	ARTICLE	IF	CITATIONS
605	Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects. <i>Oncotarget</i> , 2017, 8, 17313-17327.	0.8	31
606	A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and <i>span-leukemia</i> antigens. <i>Oncotarget</i> , 2017, 8, 43915-43924.	0.8	12
607	Granulocyte macrophage colony-stimulating factor predicts postoperative recurrence of clear-cell renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 24527-24536.	0.8	6
608	Immunobiology and immunotherapy in genitourinary malignancies. <i>Annals of Translational Medicine</i> , 2016, 4, 270-270.	0.7	14
609	Overview of Current Immunotherapies Targeting Mutated KRAS Cancers. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 2158-2175.	1.0	4
610	Renal cell carcinoma drug and cell therapy: today and tomorrow. <i>Research Results in Pharmacology</i> , 2018, 4, 17-25.	0.3	1
611	The status, limitation and improvement of adoptive cellular immunotherapy in advanced urologic malignancies. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2015, 27, 128-37.	0.7	12
612	Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications. <i>Asian Journal of Andrology</i> , 2014, 16, 364.	0.8	15
613	New treatment modalities with vaccine therapy in renal cell carcinoma. <i>Urology Annals</i> , 2019, 11, 119.	0.3	9
614	Current status of cancer immunotherapy. <i>Journal of Stem Cells and Regenerative Medicine</i> , 2014, 10, 8-13.	2.2	17
615	Collaboration in medical treatment to use Nivolumab against oral cancer, Clinical Oncologist and Oral and Maxillofacial surgeon. <i>Journal of Japanese Society of Oral Oncology</i> , 2018, 30, 135-143.	0.0	1
616	A Complex Metabolic Network Confers Immunosuppressive Functions to Myeloid-Derived Suppressor Cells (MDSCs) within the Tumour Microenvironment. <i>Cells</i> , 2021, 10, 2700.	1.8	25
617	Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy. <i>Biomarker Research</i> , 2021, 9, 77.	2.8	41
618	The TNF- $\hat{\pm}$ /TNFR2 Pathway: Targeting a Brake to Release the Anti-tumor Immune Response. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 725473.	1.8	21
619	Molecular Immunotherapeutics and Vaccines for Renal Cell Carcinoma and Its Vasculature. , 2013, , 371-383.		0
620	Development of an Ideal and Potent Cancer Immunotherapy Designed by Consideration of HLA Polymorphism. <i>Major Histocompatibility Complex</i> , 2013, 20, 45-56.	0.2	0
621	Development of Antitumor Cellular Immunity. , 2013, , 107-133.		0
622	MHC Class I Antigens and the Tumor Microenvironment. , 2013, , 253-286.		0

#	ARTICLE	IF	CITATIONS
623	Approaches to Immunologic Monitoring of Clinical Trials. , 2013, , 663-694.		0
624	Therapeutic Vaccines and Immunotherapy in Castration-Resistant Prostate Cancer: Current Progress and Clinical Applications. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e166-e170.	1.8	4
625	Cancer Immunotherapy: Vaccines. , 2014, , 347-370.		0
626	Immunotherapy in Renal Cell Carcinoma. , 2014, , 125-147.		0
627	Recent Developments in the Active Immunotherapy of Renal Cell Cancer. , 2014, , 171-178.		0
628	Myeloid-Derived Suppressor Cells in Tumor-Induced T Cell Suppression and Tolerance. , 2014, , 99-150.		2
629	How T Cells Single Out Tumor Cells: "And That Has Made All the Difference", 2014, , 13-20.		0
630	Prostate Cancer Vaccines Generated with the Disruptive RNActive® Technology Follow the Path Paved by Sipuleucel-T and Prostvac-VF. , 2014, , 155-169.		0
631	Cancer of the Kidney. , 2014, , 1416-1444.e5.		1
632	Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future. , 2015, , 471-490.		1
633	Vaccines in RCC: Clinical and Biological Relevance. , 2015, , 483-525.		0
634	Regulatory T Cells in Cancer Patients and Their Roles in Cancer Development/Progression. MOJ Immunology, 2014, 1, .	11.0	2
635	Selection and Monitoring of Patients for Immunotherapy (Peptide Vaccines). , 2015, , 63-84.		0
636	Peptide Vaccine: Overview. , 2015, , 1-13.		0
637	Combined Immunotherapy Against Cancer: Limited Efficacy of Transcutaneous Immunization and Low-dose Cyclophosphamide. Cancer and Oncology Research, 2015, 3, 1-9.	0.2	0
638	Antitumor Effects of IL-12 in Preclinical Studies. SpringerBriefs in Immunology, 2016, , 21-41.	0.1	0
639	Tumor Immunology and Immunotherapy in Cancer Patients. , 2016, , 425-442.		2
640	Cancer Vaccines. , 2016, , 295-333.		0

#	ARTICLE	IF	CITATIONS
641	Translational Research and Immunotherapy in Lung Cancer. , 2016, , 255-296.		0
642	Immunotherapy for Renal Cell Cancer (RCC). , 2017, , 295-317.		0
643	The Present Status and Future Prospects of Cancer Immunotherapy Using Active Immunization of Tumor-Associated Antigens. Major Histocompatibility Complex, 2018, 25, 40-49.	0.2	0
644	Anticancer Immunotherapy: Prospects and Challenges. , 2019, , 189-228.		0
645	Application of neoantigens in malignant tumor treatment and prognosis evaluation. World Chinese Journal of Digestology, 2019, 27, 287-292.	0.0	0
646	Neutrophil as a multifunctional relay in immune system. Russian Journal of Infection and Immunity, 2019, 9, 9-38.	0.2	14
649	Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future. , 2020, , 761-783.		1
650	Recent advances in functionalized upconversion nanoparticles for light-activated tumor therapy. RSC Advances, 2021, 11, 35472-35488.	1.7	12
651	Applications of Cutting-Edge Immunoproteomics Technology in Human Immunotherapy. , 2020, , 121-159.		0
652	In Silico Model Estimates the Clinical Trial Outcome of Cancer Vaccines. Cells, 2021, 10, 3048.	1.8	4
653	Multi-peptide immunotherapeutic vaccine for renal cell carcinoma: getting the troops all worked up. Translational Andrology and Urology, 2012, 1, 229-233.	0.6	0
654	Therapeutic challenges in renal cell carcinoma. American Journal of Clinical and Experimental Urology, 2015, 3, 77-90.	0.4	9
655	Immunotherapy in renal cell cancer: the more the merrier?. Translational Andrology and Urology, 2013, 2, 89-91.	0.6	0
656	Does patient-tailored immunotherapy pave the way for new renal cell carcinoma treatment perspectives?. Translational Andrology and Urology, 2013, 2, 85-8.	0.6	0
657	Harnessing Vaccines to Treat Cancers. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2015, 32, 27S-30S.	0.6	0
658	Editors' Choice Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity. Nagoya Journal of Medical Science, 2019, 81, 1-18.	0.6	18
659	TGF- β Enhances the Anti-inflammatory Effect of Tumor- Infiltrating CD33+11b+HLA-DR Myeloid-Derived Suppressor Cells in Gastric Cancer: A Possible Relation to MicroRNA-494. Asian Pacific Journal of Cancer Prevention, 2020, 21, 3393-3403.	0.5	3
660	Transcutaneous tumor vaccination combined with anti-programmed death-1 monoclonal antibody treatment produces a synergistic antitumor effect. Acta Biomaterialia, 2022, 140, 247-260.	4.1	25

#	ARTICLE	IF	CITATIONS
661	Injectable and Biodegradable Chitosan Hydrogel-Based Drug Depot Contributes to Synergistic Treatment of Tumors. <i>Biomacromolecules</i> , 2021, 22, 5339-5348.	2.6	17
662	Landscape of Immunotherapy in Genitourinary Malignancies. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 143-192.	0.8	2
663	Antitumor Peptide-Based Vaccine in the Limelight. <i>Vaccines</i> , 2022, 10, 70.	2.1	10
664	TGF- β 2 Enhances the Anti-inflammatory Effect of Tumor- Infiltrating CD33+11b+HLA-DR Myeloid-Derived Suppressor Cells in Gastric Cancer: A Possible Relation to MicroRNA-494. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 3393-3403.	0.5	7
665	Myeloid Diagnostic and Prognostic Markers of Immune Suppression in the Blood of Glioma Patients. <i>Frontiers in Immunology</i> , 2021, 12, 809826.	2.2	8
666	Case Report: Pathological Complete Response in a Lung Metastasis of Phyllodes Tumor Patient Following Treatment Containing Peptide Neoantigen Nano-Vaccine. <i>Frontiers in Oncology</i> , 2022, 12, 800484.	1.3	4
667	The role of DNA mismatch repair in immunotherapy of human cancer. <i>International Journal of Biological Sciences</i> , 2022, 18, 2821-2832.	2.6	20
668	Personalized peptide vaccines. , 2022, , 175-191.		0
669	Combinatorial immunotherapy strategies for cancer vaccines. , 2022, , 137-154.		0
670	The Importance of Being Presented: Target Validation by Immunopeptidomics for Epitope-Specific Immunotherapies. <i>Frontiers in Immunology</i> , 2022, 13, 883989.	2.2	20
671	Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2555-2566.	3.2	31
678	Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: an Open-Label, Multicenter, Phase Ib Study. <i>Clinical Cancer Research</i> , 2022, 28, 2818-2829.	3.2	12
679	Computational design of immunogenic peptide constructs comprising multiple human leukocyte antigen restricted dengue virus envelope epitopes. <i>Journal of Molecular Recognition</i> , 2022, 35, e2961.	1.1	5
680	The Nitrogen Mustards. <i>Pharmacological Reviews</i> , 2022, 74, 552-599.	7.1	13
681	Potential association factors for developing effective peptide-based cancer vaccines. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
682	De-risking clinical trial failure through mechanistic simulation. <i>Immunotherapy Advances</i> , 2022, 2, .	1.2	2
683	Epigenetic Mediated Regulation of Cancer-Testis/Germline Antigen and Its Implication in Cancer Immunotherapy: A Treasure Map for Future Anticipatory Medicine. <i>Cognitive Systems Monographs</i> , 2022, , 149-166.	0.1	0
684	Biocomputational characterisation of MBO_200107 protein of <i>Mycobacterium tuberculosis</i> variant <i>caprae</i> : a molecular docking and simulation study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 7204-7223.	2.0	2

#	ARTICLE	IF	CITATIONS
685	A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 827-840.	2.0	3
686	Mitigating the prevalence and function of myeloid-derived suppressor cells by redirecting myeloid differentiation using a novel immune modulator. , 2022, 10, e004710.		3
687	Computational design for identification of human anti-MUC1 heteroclitic peptides in treatment of HER2-positive breast cancer through neural network training and monomeric based design. <i>Current Cancer Drug Targets</i> , 2022, 22, .	0.8	0
688	Personalized Cancer Vaccines Targeting Neoantigens. , 2022, , 1-21.		0
689	CD36 and Its Role in Regulating the Tumor Microenvironment. <i>Current Oncology</i> , 2022, 29, 8133-8145.	0.9	3
690	Phase I/II study of multi-peptide cancer vaccine IMA901 after single-dose cyclophosphamide in Japanese patients with advanced renal cell cancer with long-term follow up. <i>International Journal of Urology</i> , 0, , .	0.5	1
691	Adjuvant Treatment for Breast Cancer Patients Using Individualized Neoantigen Peptide Vaccination—A Retrospective Observation. <i>Vaccines</i> , 2022, 10, 1882.	2.1	1
692	The Roles of MiRNAs (MicroRNAs) in Melanoma Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14775.	1.8	3
693	Regulatory Landscapes in Approval of Cancer Vaccines. , 2022, , 325-347.		0
694	Inflammation in Urological Malignancies: The Silent Killer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 866.	1.8	6
695	Chimeric antigen receptor-modified cells for the treatment of solid tumors: First steps in a thousand-mile march. , 2023, , 97-131.		0
696	Integrating immunopeptidome analysis for the design and development of cancer vaccines. <i>Seminars in Immunology</i> , 2023, 67, 101750.	2.7	3
697	The impact of immunopeptidomics: From basic research to clinical implementation. <i>Seminars in Immunology</i> , 2023, 66, 101727.	2.7	17
698	The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	23
699	Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C. <i>Journal of Pharmaceutical Analysis</i> , 2023, 13, 616-624.	2.4	8
701	NetCleave: An Open-Source Algorithm for Predicting C-Terminal Antigen Processing for MHC-I and MHC-II. <i>Methods in Molecular Biology</i> , 2023, , 211-226.	0.4	1
707	Cancer Vaccines. , 2023, , 191-210.e9.		0
715	Case Report: Targeting of individual somatic tumor mutations by multi-peptide vaccination tailored for HLA class I and II presentation induces strong CD4 and CD8 T-cell responses in a patient with metastatic castration sensitive prostate cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0

#	ARTICLE	IF	CITATIONS
716	Novel Targets in Development for Advanced Renal Cell Carcinoma. , 2023, , 309-342.		0